Clinical significance of FAT4 protein expression in pancreatic cancer

Yao ZHANG; Kai ZHANG; Chao MA

doi:10.3969/j.issn.1001-5256.2022.12.021

Volume 38 Issue 12

Dec. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(12): 2802-2806

PDF( 2898 KB)

Clinical significance of FAT4 protein expression in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.021

Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China

Research funding:

Science and Technology Key Project of Henan Province (162102310315)

More Information

Corresponding author: MA Chao, mjc1566@sina.com (ORCID: 0000-0002-6894-1259)
Received Date: 2022-05-09
Accepted Date: 2022-06-22
Published Date: 2022-12-20

Abstract

Abstract

Objective To detect the expression of fat atypical cadherin 4 (FAT4) in pancreatic cancer tissue and para-carcinoma tissue, and explored the role of FAT4 in the pathogenesis of pancreatic cancer. Methods Pancreatic cancer tissue samples and adjacent tissue samples were collected from 79 patients who underwent radical resection in The Affiliated Cancer Hospital of Zhengzhou University from January 2015 to January 2017 and were diagnosed with pancreatic ductal adenocarcinoma based on postoperative pathology. Immunohistochemistry was used to measure the protein expression of FAT4 in pancreatic cancer tissue and adjacent tissue, and the association between FAT4 expression and clinicopathological features was analyzed. The Mann-Whitney U test was used for comparison of ranked data between groups, and the chi-square test was used for comparison of categorical data. A Spearman correlation analysis was used to investigate the correlation between variables. Results The down-regulated expression of FAT4 was detected in 72.15% (52/79) of pancreatic cancer tissue, which was significant higher than that in para-cancer tissues (21.52%, 17/79, P < 0.001). There was a significant difference in backache between the low FAT4 expression group and the high FAT4 expression group (χ²=4.115, P=0.042), and there were also significant differences in lymph node metastasis and perineural invasion between these two groups (χ²=8.743 and 4.925, P=0.003 and 0.026). TNM staging and degree of tumor differentiation were ranked variables, and the analysis of the association between these two variables and FAT4 expression based on Spearman rank correlation coefficient showed that FAT4 expression was not associated with the TNM staging and degree of tumor differentiation of pancreatic cancer (all P > 0.05). Conclusion The expression of FAT4 was significantly down-regulated in pancreatic cancer, suggesting that FAT4 may promote the invasion and infiltration of pancreatic cancer.
- Pancreatic Neoplasms,
- Immunohistochemistry,
- Pathology, Clinical

FullText(HTML)

References(11)

References

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	MAHONEY PA, WEBER U, ONOFRECHUK P, et al. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily[J]. Cell, 1991, 67(5): 853-868. DOI: 10.1016/0092-8674(91)90359-7.
[3]	RAUCH TA, WANG Z, WU X, et al. DNA methylation biomarkers for lung cancer[J]. Tumour Biol, 2012, 33(2): 287-296. DOI: 10.1007/s13277-011-0282-2.
[4]	ITO T, TANIGUCHI H, FUKAGAI K, et al. Inhibitory mechanism of FAT4 gene expression in response to actin dynamics during Src-induced carcinogenesis[J]. PLoS One, 2015, 10(2): e0118336. DOI: 10.1371/journal.pone.0118336.
[5]	JUNG HY, CHO H, OH MH, et al. Loss of fat atypical cadherin 4 expression is associated with high pathologic T stage in radically resected gastric cancer[J]. J Gastric Cancer, 2015, 15(1): 39-45. DOI: 10.5230/jgc.2015.15.1.39.
[6]	ALLEN PJ, KUK D, CASTILLO CF, et al. Multi-institutional validation study of the american joint commission on cancer (8th Edition) changes for T and N staging in patients with pancreatic adenocarcinoma[J]. Ann Surg, 2017, 265(1): 185-191. DOI: 10.1097/SLA.0000000000001763.
[7]	MORRIS LG, KAUFMAN AM, GONG Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation[J]. Nat Genet, 2013, 45(3): 253-261. DOI: 10.1038/ng.2538.
[8]	VALLETTA D, CZECH B, SPRUSS T, et al. Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma[J]. Carcinogenesis, 2014, 35(6): 1407-1415. DOI: 10.1093/carcin/bgu054.
[9]	KIM KT, KIM BS, KIM JH. Association between FAT1 mutation and overall survival in patients with human papillomavirus-negative head and neck squamous cell carcinoma[J]. Head Neck, 2016, 38 Suppl 1: E2021-E2029. DOI: 10.1002/hed.24372.
[10]	YOSHIDA S, YAMASHITA S, NIWA T, et al. Epigenetic inactivation of FAT4 contributes to gastric field cancerization[J]. Gastric Cancer, 2017, 20(1): 136-145. DOI: 10.1007/s10120-016-0593-5.
[11]	FURUKAWA T, SAKAMOTO H, TAKEUCHI S, et al. Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas[J]. Sci Rep, 2015, 5: 8829. DOI: 10.1038/srep08829.

Relative Articles

[1]	Guodong SHI, Zipeng LU, Kuirong JIANG. Diagnosis and treatment of dyspepsia associated with pancreatic tumors[J]. Journal of Clinical Hepatology, 2023, 39(12): 2770-2774. doi: 10.3969/j.issn.1001-5256.2023.12.004
[2]	Min LIU, Weijian CHEN, Zhengzhen ZHOU, Xiaomei QIN, Rong WEN, Nan JIANG, Linzhi KUANG, Taiqing ZHENG, Liqiong ZHANG, Shuangjie LI. Histopathological characteristics of the liver in children with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(5): 1144-1149. doi: 10.3969/j.issn.1001-5256.2023.05.021
[3]	Li WANG, Yongfeng YANG. Diagnosis and treatment of autoimmune hepatitis: The indispensable role of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 504-510. doi: 10.3969/j.issn.1001-5256.2023.03.004
[4]	Qian ZHAO, Yongliang FENG, Yan WANG, Zhigang WEI. Clinical characteristics of patients with pancreatic cancer combined with new onset diabetes mellitus[J]. Journal of Clinical Hepatology, 2022, 38(12): 2780-2786. doi: 10.3969/j.issn.1001-5256.2022.12.018
[5]	Yuanjiao GAO, Yanjie LIN, Liu YANG, Xiaoyue BI, Wen DENG, Tingting JIANG, Fangfang SUN, Yao LU, Lu ZHANG, Minghui LI, Yao XIE. Liver histopathology and clinical features of autoimmune hepatitis with different antibody statuses[J]. Journal of Clinical Hepatology, 2022, 38(12): 2744-2749. doi: 10.3969/j.issn.1001-5256.2022.12.012
[6]	Tingting BI, Sihui HOU, Yan LIU. Expression of neural precursor cell expressed developmentally downregulated 4-1 in pancreatic cancer tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2022, 38(3): 617-621. doi: 10.3969/j.issn.1001-5256.2022.03.024
[7]	Bai XiaoMei, Sun RunQin, Chen XiaoLi. Clinical and pathological features of solid pseudopapillary neoplasm of the pancreas: An analysis of 14 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1047-1051. doi: 10.3969/j.issn.1001-5256.2019.05.022
[8]	Jiang LiLin, Shen JianBo, Tang Hong, Lu ZhongHua. Pathological differential diagnosis of inflammatory liver injury[J]. Journal of Clinical Hepatology, 2018, 34(11): 2278-2282. doi: 10.3969/j.issn.1001-5256.2018.11.003
[9]	Zheng SuLi, Zhang TaiPing. An excerpt of laparoscopic surgery for pancreatic neoplasms: the European Association for Endoscopic Surgery clinical consensus conference（2017）[J]. Journal of Clinical Hepatology, 2017, 33(5): 816-819. doi: 10.3969/j.issn.1001-5256.2017.05.004
[10]	Chen Jie. Pathological and differential diagnoses of exocrine pancreatic tumors[J]. Journal of Clinical Hepatology, 2013, 29(1): 45-49.
[11]	Zhang WenYing, Jin ZhenDong. Endoscopic ultrasound -guided treatment for pancreatic tumor[J]. Journal of Clinical Hepatology, 2012, 28(8): 573-575+578.
[13]	Yang XiaoJing, Yang ZhuLin, Huang JiangSheng, Yang LePing, Fu Xi. Study on pathological significance in the expression of the nerve growth factor (NCF) and its mRNA in benign and malignant lesions of gallbladder.[J]. Journal of Clinical Hepatology, 2008, 24(3): 207-209.
[14]	Zhang RongGui, Tang ZhengHao, Feng Jie, Zang GuoQing, Yu YongSheng. The expression of c-myb in HCC tissues and clinical significance.[J]. Journal of Clinical Hepatology, 2008, 24(2): 106-108.
[15]	Yang LePing, Yang ZhuLin, Lan SiGen, Fu Xi, Huang JiangSheng, Luo Xin. Expression of insulin-like growth factor-binding protein-2 (IGFBP2) and matrix metalloproteinase-9 (MMP9) and its clinicopathologieal significances in benign and malignant lesions of gallbladder[J]. Journal of Clinical Hepatology, 2008, 24(6): 442-445.
[16]	Shan HaiXia, Wu AiHua, Hou JinLin, Zhu YouFu. Clinical and pathological characteristics of autoimmune liver disease.[J]. Journal of Clinical Hepatology, 2008, 24(2): 111-113.
[17]	Gu HuaPing, Liu YanRu, Shang PeiZhong. Expression of CD44v6 and C-erbB-2 in gallbladder neoplasms and their relatonship[J]. Journal of Clinical Hepatology, 2002, 18(6): 370-371.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(6)

Get Citation

PDF

XML

Article Metrics

Article views (1491) PDF downloads(39)

Clinical significance of FAT4 protein expression in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.021

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical significance of FAT4 protein expression in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.021

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content